AN ACT to amend Tennessee Code Annotated, Title 4; Title 38, Chapter 3; Title 39, Chapter 17; Title 43; Title 50; Title 53; Title 63; Title 67 and Title 68, relative to the "Tennessee Medical Cannabis Act."
HB0872 would create the “Tennessee Medical Cannabis Act,” establishing a statewide medical cannabis program for qualifying Tennessee residents. The bill sets up a patient and caregiver card system, defines a list of qualifying medical conditions, and requires certification or medical records from approved healthcare providers. It also creates a new Tennessee Medical Cannabis Program Commission to administer the program, issue cards and licenses, promulgate rules, oversee inspections and enforcement, and maintain electronic registries and a seed-to-sale track-and-trace system.
The bill authorizes a regulated market for cultivation, processing, manufacturing, transportation, testing, dispensing, and sale of medical cannabis and medical cannabis-infused products. It creates two initial license categories for phase 1 operations—urban omni and rural vertically integrated licenses—with detailed application requirements, background checks, ownership residency requirements, and deadlines for provisional and final approval. The bill also imposes product testing, packaging, labeling, security, and advertising rules, and it preempts conflicting state criminal and civil laws for conduct that complies with the act.
If enacted, the bill would significantly amend Tennessee law by carving medical cannabis activity out of existing criminal prohibitions and replacing them with a licensing and regulatory framework. It would affect Title 39 controlled-substances enforcement, Title 68 public health provisions, and related tax, agriculture, revenue, and administrative statutes by creating a new commission, a medical cannabis fund, and new tax and fee structures. It would also require state agencies and law enforcement to use patient and license registries, and it would authorize local governments to opt out of medical cannabis businesses by supermajority vote within a specified window.
The bill text reflects a strongly supportive posture toward medical cannabis, emphasizing patient access, public health options, agricultural development, research, and opioid-overdose reduction. The absence of committee transcripts or recorded votes means there is no documented debate or formal legislative sentiment in the provided context. Based on the bill’s structure and findings, the measure is framed as a comprehensive, implementation-focused legalization proposal rather than a narrow policy change.
The main points of contention likely concern the scope of legalization, the size and structure of the new regulatory apparatus, and the balance between patient access and control measures. The bill tightly regulates who may participate, imposes substantial application fees, limits ownership interests, requires residency, and creates a commission with extensive authority over licensing and enforcement. Local control is also a likely issue because counties and municipalities may ban medical cannabis businesses only by a two-thirds vote and only within a limited timeframe. Additional friction may arise over taxation, the use of cannabis for minors through caregivers, workplace protections, and the bill’s preemption of existing criminal laws.